

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
20 February 2003 (20.02.2003)

PCT

(10) International Publication Number  
**WO 03/013268 A1**

(51) International Patent Classification<sup>7</sup>: **A23K 1/16**, 1/18

(21) International Application Number: PCT/GB02/03579

(22) International Filing Date: 2 August 2002 (02.08.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
0119052.9 3 August 2001 (03.08.2001) GB

(71) Applicant (for all designated States except US): **MARS UK LIMITED** [GB/GB]; 3D Dundee Road, Slough, Berkshire SL1 4LG (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **HEATON, Paul, Richard** [GB/GB]; Waltham Centre for Pet Nutrition, Waltham-on-the-Wolds, Leicestershire LE14 4RT (GB). **SMITH, Brigitte, H., E.** [GB/GB]; Waltham Centre for Pet Nutrition, Freeby Lane, Waltham-on-the-Wolds,

Melton Mowbray, Leicestershire LE14 4RT (GB). **RAWLINGS, John, Merrit** [GB/GB]; Waltham Centre for Pet Nutrition, Waltham-on-the-Wolds, Leicestershire LE14 4RT (GB).


(74) Agents: **CORNISH, Kristina, Victoria, Joy** et al.; Kilburn & Strode, 20 Red Lion Street, London WC1R 4PJ (GB).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: FOODSTUFF



(57) Abstract: The present invention provides nutritional components, for use in reducing nucleic acid damage in a companion animal. The nutritional components are vitamin E, vitamin C and a carotenoid. These components can be used in a foodstuff for reducing nucleic acid damage in a companion animal.



WO 03/013268 A1

**Published:**

- *with international search report*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

Foodstuff

The present invention provides nutritional components, for use in reducing nucleic acid damage in a companion animal.

5

Identifying the mechanisms which are involved in determining species-specific life spans remains one of the outstanding questions of biological ageing.

Evolution theory proposed that long-lived species are able to provide for their  
10 longevity by a more durable soma, including enhanced cellular resistance to stress. Normal cellular processes like respiration and other metabolic activities generate a variety of stresses in the cellular micro-environment. These include oxidative stress, heat energy and ionic and pH changes produced during normal biochemical reactions, all of which are known to cause damage to cell organelles (e.g. mitochondria, Golgi  
15 apparatus, the cytosol, the plasma membrane, the cytoskeleton, lysosomes and the nucleus) and cellular macromolecules (e.g. proteins, polysaccharides, nucleic acids, lipids, phospholipids). Some of the damage caused by these stresses is irreversible.

Accordingly, there is a desire to be able to reduce damage to one or more components  
20 of the cellular microenvironment, such as cell organelles or cell macromolecules.

The present invention provides nutritional intervention for use in reducing damage to nucleic acid.

25 Factors which affect cell organelles and cell macromolecules are considered to be wide-ranging. They may include environmental influences (temperature pressure), geographical factors, phenotypic factors and nutritional intervention (diet).

The present invention has determined, and provides, nutritional intervention for use in  
30 reducing damage to the cell macromolecules which are nucleic acid molecules.

Accordingly, the present invention provides the use of vitamin E, vitamin C and a carotenoid in the manufacture of a foodstuff for reducing nucleic acid damage in a companion animal.

5

The nucleic acid may be deoxyribonucleic acid (DNA) or ribonucleic acid (RNA).

Vitamin E is a collective term for several biologically similar compounds, including those called tocopherols and tocotrienols, which share the same biological activity.

10

The most biologically active biological form of vitamin E (also the most active antioxidant) in animal tissue is alpha-tocopherol. Vitamin E cannot be synthesised *in vivo*. Vitamin E protects against the loss of cell membrane integrity, which adversely alters cellular and organelle function.

15

Units of vitamin E can be expressed as International Units (IU), where 1 IU of alpha-tocopherol equals 1mg of alpha-tocopherol. Other vitamin E compounds have their IU determined by their biopotency in comparison to alpha-tocopherol as described in McDowell, L.R (1989) Vitamin E: In vitamins in Animal Nutrition, Chapter 4, page 96, Academic Press, UK.

20

The vitamin E according to the first aspect of the invention may be in any form. It may be a tocopherol or a tocotrienol. It may be alpha-tocopherol, (d- $\alpha$  or dl- $\alpha$ ) beta-tocopherol (d- $\beta$  or dl- $\beta$ ), gamma-tocopherol (d- $\gamma$  or dl- $\gamma$ ), delta-tocopherol, alpha-tocotrienol, beta-tocotrienol, gamma-tocotrienol or delta-tocotrienol. Preferably it is

25

alpha-tocopherol.

The source of the vitamin E is not limiting. Preferred vitamin E sources include vitamin E acetate, (e.g. tocopherol acetate), vitamin E acetate adsorbate or vitamin E

acetate spray dried. Preferred sources are synthetic although natural sources may be used.

5 The form of administration of the vitamin E is not limiting. It may be in the form of a diet, foodstuff or a supplement. Hereinafter in this text, the term "foodstuff" covers all of foodstuff, diet and supplement. Any of these forms may be solid, semi-solid or liquid.

10 The supplement is particularly useful to supplement a diet or foodstuff which does not contain sufficiently high levels of one or more of the components according to the invention. The concentrations of the components in the supplement may be used to "top up" the levels in the animal's diet or foodstuff. This can be done by including a quantity of the supplement with the animal's diet or by additionally feeding the animal a quantity of the supplement. The supplement can be formed as a foodstuff with  
15 extremely high levels of one or more components of the invention which requires dilution before feeding to the animal. The supplement may be in any form, including solid (e.g. a powder), semi-solid (e.g. a food-like consistency/gel), a liquid or alternatively, it may be in the form of a tablet or capsule. The liquid can conveniently be mixed in with the food or fed directly to the animal, for example via a spoon or via  
20 a pipette-like device. The supplement may be high in one or more components of the invention or may be in the form of a combined pack of at least two parts, each part containing the required level of one or more component.

25 Preferably the vitamin E is incorporated into a commercial petfood product or a commercial dietary supplement. The petfood product may be a dry, semi-dry, a moist or a liquid (drink) product. Moist products include food which is sold in tins or foil containers and has a moisture content of 70 to 90%. Dry products include food which have a similar composition, but with 5 to 15% moisture and presented as biscuit-like kibbles. The diet, foodstuff or supplement is preferably packaged. In this way the  
30 consumer is able to identify, from the packaging, the ingredients in the food and

identify that it is suitable for the dog or cat in question. The packaging may be metal (usually in the form of a tin or flexifoil), plastic, paper or card. The amount of moisture in any product may influence the type of packaging which can be used or is required.

5

The foodstuff according to the present invention encompasses any product which a companion animal may consume in its diet. Thus, the invention covers standard food products, as well as pet food snacks (for example snack bars, biscuits and sweet products). The foodstuff is preferably a cooked product. It may incorporate meat or animal derived material (such as beef, chicken, turkey, lamb, blood plasma, marrowbone etc, or two or more thereof). The foodstuff alternatively may be meat free (preferably including a meat substitute such as soya, maize gluten or a soya product) in order to provide a protein source. The product may contain additional protein sources such as soya protein concentrate, milk proteins, gluten etc. The product may also contain a starch source such as one or more grains (e.g. wheat, corn, rice, oats, barely etc) or may be starch free. A typical dry commercial dog and cat food contains about 30% crude protein, about 10-20% fat and the remainder being carbohydrate, including dietary fibre and ash. A typical wet, or moist product contains (on a dry matter basis) about 40% fat, 50% protein and the remainder being fibre and ash. The present invention is particularly relevant for a foodstuff as herein described which is sold as a diet, foodstuff or supplement for a cat or dog.

The companion animal of the present invention is not limited. It does not relate to human animals. Companion animals include the domestic cat and the domestic dog, as well as the horse, fish, bird, rabbit and guinea pig. In the present text the terms “domestic” dog and “domestic” cat mean dogs and cats, in particular *Felis domesticus* and *Canis domesticus*.

The concentration of vitamin E in a product (solid or liquid or any other form) can easily be determined. For example, it can be determined by HPLC methodology.

30

Preferably, the vitamin E of the foodstuff according to the first aspect of the invention is at a level of from 25IU/400kcal diet. Throughout this text, references to concentrations per kcal are to kcal total metabolisable energy intake. The determination of calorie density can be identified using Nutritional Requirements of Dogs (1985) National Research Council (U.S.) National Academy Press Washington DC, ISBN: 0-309-03496-5 or Nutritional Requirements of Cats (1986) National Research Council (U.S.) National Academy Press Washington DC, ISBN: 0-309-03682-8. Preferred levels for cats are from 30IU/400kcal, from 35IU/400kcal, from 40IU/400kcal, from 45IU/400 kcal, from 50IU/400 kcal, from 55IU/400kcal, up to about 100IU/400kcal or above. Preferred levels for dogs are from 30IU/400kcal, from 40IU/400kcal, from 45IU/400kcal, from 50IU/400kcal, from 55IU/400kcal, from 60IU/400kcal, from 65IU/400kcal, up to about from 100IU/400kcal or above.

The first aspect of the invention, also includes vitamin C (ascorbic acid).

Vitamin C is a water-soluble substance. It is synthesised *de novo* in both the domestic cat and the domestic dog. Because it is synthesised *in vivo*, the effect of vitamin C supplements in dog and cat has not previously been investigated. In particular, the effect of vitamin C supplementation in cat and dog, as a potential antioxidant and in combination with vitamin E supplementation has not been investigated.

The vitamin C according to the first aspect of the invention may be in any form. It may be liquid, semi-solid or solid. Preferably it is a heat stable form such as a form of calcium phosphate.

The source of the vitamin C is not limiting. Preferred vitamin C sources include crystalline ascorbic acid (optionally pure), ethylcellulose coated ascorbic acid, calcium phosphate salts of ascorbic acid, ascorbic acid-2-monophosphate salt or ascorbyl-2-

monophosphate with small traces of the disphosphate salt and traces of the triphosphate salt, calcium phosphate, or for example, fresh liver.

5 The level of vitamin C in a product (solid, liquid or any other form) can easily be determined. For example, it can be determined by HPLC methodology.

10 A further useful point in relation to the use of vitamin E in combination with vitamin C is their potential to act synergistically. This may be assisted by the fact that vitamin E is lipid soluble and vitamin C is water-soluble. Alpha-tocopherol is known to sit in the lipid membrane. Ascorbate and alpha-tocopherol, for example, interact at the interface between cell membranes or lipoproteins and water. Ascorbic acid rapidly reduces alpha-tocopherol radicals in membranes to regenerate alpha-tocopherol. The preferred concentration of vitamin C according to the first aspect of the invention is a level which preferably increases the plasma vitamin C level of an animal by up to  
15 about 25% (preferably 25% or more) in comparison with when the animal is fed a control diet, such that its total vitamin C consumption is (for both a cat or a dog) 5mg/400kcal diet. Levels of vitamin C which do not achieve this increase are still covered by the first aspect of the invention. Levels of vitamin C according to the first aspect of the invention include from 10, 12, 15, 17, 20, 22, 25, 27, 30, 32, 38, 40, 42,  
20 48 up to about 50 mg/400kcal diet. Preferred levels for the cat are the above options from 10 to 48 mg/400kcal and for the dog, the above options from 12 to 50 mg/400kcal. Levels above 55 mg/400kcal provide no added benefit and are usually best avoided.

25 The first aspect of the invention also includes a carotenoid.

The carotenoids are a group of red, orange and yellow pigments predominantly found in plant foods, particularly fruit and vegetables, and in the tissues of animals which eat the plants. They are lipophilic compounds. Some carotenoids act as a precursors of  
30 vitamin A, some cannot. This property is unrelated to their antioxidant activity.



Carotenoids can act as powerful antioxidants. Carotenoids are absorbed in varying degrees by different animal species. Carotenoids may be classified into two main groups; those based on carotenes and those based on xanthophylls (which include oxygenated compounds). Common carotenoids include; beta-carotene, alpha-carotene, lycopene, lutein, zeaxanthin and astaxanthin. Carotenoids are not proven to be essential nutrients in the feline or canine diet. Unlike humans and dogs, the cat is unable to convert the precursor beta-carotene into the active vitamin A form since the required enzyme necessary for this conversion is absent from the intestinal mucosa in cats (they do not possess the dioxygenase enzyme which is needed to cleave the carotene molecule).

This invention shows that carotenoids can be absorbed by the domestic cat and dog (to give an increased plasma concentration) and can contribute to a reduction in DNA damage. Further, the present invention has demonstrated that the carotenoids can be absorbed following their incorporation into a commercial product. As mentioned above, the components of the first aspect of the invention may act synergistically. Vitamin E is able to protect beta-carotene from oxidation and may have a sparing effect on beta-carotene. Vitamin E is thought to protect the chemical bonds of beta-carotene from being oxidised.

The source of the carotenoids is not limiting and can include natural and synthetic sources. In particular, the preferred source is a natural source and includes; marigold meal and lucerne meal (sources of lutein); tomato meal, red palm oil, tomato powder, tomato pomace/pulp (sources of beta-carotene and lycopene). Sources include oils high in carotenoid levels and pure manufactured carotenoids such as lutein, violaxanthin, cryptoxanthin, bixin, zeaxanthin, apo-EE (Apo-8-carotenic acid ethylester), canthaxanthin, citranaxanthin, achinenone, lycopene and capsanthin. Preferred levels of total carotenoids are from 0.01mg/400kcal, or from 0.2mg/400kcal or from 1mg/400kcal or from 2mg/400kcal.

The concentrations of the following carotenoids are preferably:

Beta-carotene: 0.01 to 1.5mg/400kcal, preferably 0.5 to 1mg/400kcal

Lycopene: 0.01 to 1.5mg/400kcal, preferably 0.5 to 1mg/400kcal

Lutein: 0.05 to 1.5mg/400kcal, preferably 0.5 to 1mg/400kcal.

- 5 In particular, the present invention provides for a combination of carotenoids in the first aspect of the invention.

Preferred sources of the combined carotenoids include;

Red Palm Oil and Marigold Meal

- 10 Tomato Powder, Marigold Meal and Lucerne

Tomato Pomace and Marigold Meal.

The level of carotenoid in a product is easily determined. For example, it can be determined by HPLC methodology.

15

The first aspect of the invention may include taurine.

- 20 Taurine is an unusual amino acid found in a wide variety of animal species. Taurine is an essential nutrient for the cat which, unlike the dog, is unable to synthesise taurine from precursor amino acids. It is thought that taurine protects cellular membranes from toxic components including oxidants. The increase in vitamin taurine levels in an animal diet can contribute to a reduction in free radicals and therefore a reduction in DNA damage in the animal, in particular in combination with the other components of the invention.

25

The taurine according to the first aspect of the invention may be in any form. It may be powdered, crystalline, semi-solid or liquid.

- 30 The source of the taurine is not limiting. Preferred taurine sources include aminoethylsulfonic acid (C<sub>2</sub>H<sub>7</sub>N<sub>0</sub>S<sub>3</sub>). Sources may be natural or synthetic.

Suitable concentrations of taurine for use according to the first aspect of the invention are usually determined, to some extent as to the processing of the product (for example, whether the product is dry or canned). To maintain plasma taurine levels in the cat at the normal range ( $>60\mu\text{mol/l}$ ), a canned (moist) diet must supply at least 39mg of taurine/kg body weight per day and a dry diet at least 19mg/kg body weight per day. The first aspect of an invention provides, for a product which is not subjected to a high temperature method (such as canning) a preferred level of from about 80mg/400kcal, more preferably from about 100, increasing even more preferably from 120, 150, 180, 200, 220, 250, 280, 300, 320, 350, 400 and above in mg/400kcal diet. In a product which is processed such as by high temperature, levels according to the invention are preferably from about 380mg/400kcal, more preferably from about 400, increasing even more preferably from 420, 450, 480, 500, 520, 550, 580, 600, 620, 650, 700 and above in mg/400kcal diet.

The concentration of taurine in a product (solid liquid or in any other form) can be easily determined. For example, it can be determined by HPLC chromatography.

As described above, the invention includes vitamin E and other components. Useful combinations of the components (preferably in a canned or dry petfood) include;

Vitamin E, vitamin C, taurine, red palm oil and marigold meal

Vitamin E, vitamin C, taurine, tomato powder, marigold meal and lucerne

Vitamin E, vitamin C, taurine, tomato powder and marigold meal

Vitamin E, vitamin C, taurine, tomato powder and lucerne

Vitamin E, taurine, tomato pomace and marigold meal.

A combination of the present invention is;

		Approx. active component <u>mg/400kcal after production</u> (Dry Product)
5	Vitamin C	20mg ascorbic acid
	Vitamin E	50 IU
	Taurine	200mg (500 mg in wet product)
	Lutein	0.17mg
	Lycopene	0.03mg
10	Beta-carotene	0.01mg

A further useful combination of the present invention is:

15	Vitamin E	50IU/400kcal
	Vitamin C	20mg/400kcal
	Taurine	500mg/400kcal
	Beta-carotene	0.5 to 1mg/400kcal
	Lycopene	1mg/400kcal
20	Lutein	0.5 to 1mg/400kcal

Other useful components of the foodstuff according to the invention, include; trace minerals (not direct antioxidants, but function as cofactors within antioxidant metalloenzyme systems), selenium (an essential part of the antioxidant selenoenzyme, glutathione peroxidase), copper, zinc and manganese (forming an integral part of the antioxidant metalloenzymes Cu-Zn-superoxide dismutase and Mn-superoxide dismutase).

A second aspect of the invention provides a method of reducing nucleic acid damage in an animal, the method comprising administering a foodstuff comprising vitamin E,

vitamin C and a carotenoid to said animal.

All preferred features of the first aspect also apply to the second aspect.

- 5 In accordance with the method of the second aspect, the components may be administered or consumed simultaneously, separately or sequentially.

10 With increasing evidence suggesting involvement of free radical species in the development of oxidative DNA damage, the consequences of which have been implicated in the aetiology of a number of degenerative disorders the need to accurately assess levels of DNA damage has received renewed attention. Significant levels of DNA damage have been detected in normal human cells, thought to arise from free radical attack (e.g. hydroxyl radicals) produced as a by-product of normal bodily processes.

15 A variety of defence mechanisms do exist to quench potentially damaging free radicals. Primary antioxidant defences include enzymes (catalase, superoxide dismutase and glutathione peroxidase). Secondary antioxidant defences involve excision and repair processes that remove free radical-induced DNA damage. Despite these defence systems damage still occurs within the cell and it is thought accumulation of unrepaired DNA may contribute to a variety of disorders.

25 Single-cell electrophoresis, more commonly known as the comet assay, is a simple and very sensitive method for measuring nucleic acid damage (particularly DNA damage) with the added advantage of being able to assess DNA damage at the single-cell level. The basic principle of the assay is that DNA present in all cell types can become damaged, mutated or recombine through the effects of free radical attack. DNA repair enzymes (e.g. DNA endonucleases) remove these damaged sections of DNA. This in effect leaves gaps or "DNA strand breaks" in the DNA. It is these strand breaks that the comet assay is designed to detect and quantify.

To date, the comet assay has been used for a variety of applications, including toxicological studies (Singh N.P., McCoy, M.T., Tice, R.R. & Schneider, E.L. (1988). A simple technique for quantitation of low levels of DNA damage in individual cells. Exp. Cell Biol. 175:184-191), exercise-induced damage (Hartmann, D. (1994). Free-radical theory of ageing: Increasing the functional life span. Ann. NY. Acad. Sci. 717:1-15), and measuring cell growth and DNA repair mechanisms (Duthie, S.J. & Collins, A.R. (1997) The influence of cell growth, detoxifying enzymes and DNA repair of hydrogen peroxide-mediated DNA damage (measured using the comet assay) in human cells. Free Radic. Biol. Med. 22: 717-724).

It is important to have the ability to be able to accurately measure levels of free radical damage and how dietary intervention may be able to reduce such damage in cats and dogs. We have developed and validated the comet assay (modified from the original methodology described by Singh *et al*, (Supra)), for measuring levels of DNA damage induced by free radical attack in cat and dog blood samples for inclusion in nutritional studies.

The comet assay works on the principle that free radicals, such as reactive oxygen species, attack and cause DNA strand breaks which leads to unwinding and loss of the DNA supercoil structure. Cells such as leukocytes, are embedded in agarose and layered on a microscope slide, lysed with detergent and electrophoresed under alkaline conditions. Nucleoids are formed, containing non-nucleosomal but still supercoiled DNA. Any breaks present in the DNA cause the supercoiling to relax locally and loops of DNA are then free to extend to form a comet-shaped structure with a distinct "tail" region consisting of stretched and broken DNA loops that have migrated from the nucleoid "head" when subjected to alkaline electrophoresis.

The alkaline conditions also allow strands in the broken loops to unwind and convert alkali-labile sites into DNA breaks, to contribute to the formation of the comet "head"

and "tail".

Following fluorescent staining, the intensity of the stain is related to DNA content with DNA damage being quantified by a validated visual grading system and/or  
5 computer image analysis package. Two measures of DNA damage are assessed. Firstly, endogenous (background) DNA damage, which gives an indication of naturally occurring DNA strand breaks in the cell. Secondly, artificially induced (cells treated with hydrogen peroxide) DNA damage that reflects antioxidant resistance to exogenous damage.

10

Endogenous and exogenous DNA damage gives an indication that elevated levels of damage (or the elevated stress that causes the damage) contribute to the development of secondary disease.

15 The comet assay also has proven benefits of:-

- Requiring only a small blood sample from cats and dogs,
- Sensitivity of detecting DNA damage at the single-cell level,
- Potentially high-throughput assay,
- 20 • Ease of application, flexibility and low cost.

The comet assay can be used to discern the different effects of a diet on both endogenous and exogenous DNA damage and consequently can be proposed as a simple bioassay for studying the effects that different nutritional supplements have on  
25 modulating levels of DNA damage in cats and dogs.

The present invention is described.

Figure 1: Effect of varying concentrations of hydrogen peroxide (0-250 $\mu$ M/ml) on

inducing DNA damage. Results are mean  $\pm$  SEM of 12 feline subjects. Statistical significance at  $p < 0.001$  for means with different letters.

5 Figure 2: Effect of varying concentrations of hydrogen peroxide (0-250 $\mu$ M/ml) on inducing DNA damage. Results are mean  $\pm$  SEM of 12 canine subjects. Statistical significance at  $p < 0.001$  for means with different letters.

10 Figure 3: Relationship between visual scoring and computerised image analysis of feline leukocytes for percentage DNA in tail for all classes of DNA damage. Results are mean  $\pm$  SEM (n=100 per class).

15 Figure 4: Relationship between visual scoring and computerised image analysis of feline leukocytes for tail moment for all classes of DNA damage. Results are mean  $\pm$  SEM (n=100 per class).

Figure 5: Relationship between visual scoring and computerised image analysis of feline leukocytes for tail length for all classes of DNA damage. Results are mean  $\pm$  SEM (n=100 per class).

20 Figure 6: Relationship between visual scoring and computerised image analysis of canine leukocytes for percentage DNA in tail. Results are mean  $\pm$  SEM (n=100 per class).

25 Figure 7: Relationship between visual scoring and computerised image analysis of tail moment for all classes of DNA damage for canine leukocytes. Results are mean  $\pm$  SEM (n=100 per class).

Figure 8: Relationship between visual scoring and computerised image analysis of canine leukocytes for tail length for all classes of DNA damage. Results are mean  $\pm$



SEM (n=100 per class).

5      Figure 9: Endogenous DNA damage in both the control and supplemental groups of cats. Mean values from each group are shown, with standard error mean (SEM) of the means.

10      Figure 10: Exogenous DNA damage in both the control and supplemented groups of cats. Mean values from each group are shown, with standard error mean (SEM) of the means.

15      Figure 11: Endogenous DNA damage in both the control and supplemented groups of puppies. Mean values from each group are shown, with standard error mean (SEM) of the means.

20      Figure 12: Endogenous and exogenous DNA damage in both the control and AOX supplemented groups of dogs taken pre-supplementation. Mean values from each group are shown.

25      Figure 13: Endogenous and exogenous DNA damage in both the control and AOX-supplemented groups of dogs taken at 2 months post-supplementation. Mean values from each group are shown.

30      Figure 14: Comparing baseline and 2 month post-supplementation endogenous DNA damage results between the no supplement and AOX-supplemented groups of dogs.

35      Figure 15: Comparing baseline and 2 month post-supplementation exogenous DNA damage results between the no supplement and AOX-supplemented groups of dogs.

40      Figure 16: Endogenous and exogenous DNA damage in both the control and antioxidant (AOX)-supplemented groups of dogs taken pre-supplementation. Mean

values from each group are shown. Results are expressed as mean ( $\pm$  SEM),  $n = 20$ . No significant differences were noted.

Figure 17: Endogenous and exogenous DNA damage in both the control and antioxidant (AOX)-supplemented groups of dogs taken at 2 months post-supplementation. Mean values from each group are shown. Results are expressed as mean ( $\pm$  SEM),  $n = 20$ . Asterisks denote significance of  $P < 0.005$ .

The present invention will now be described with reference to the following examples.

#### Example 1

Validation of single-cell gel electrophoresis assay (comet assay) for assessing levels of DNA damage in canine and feline leucocytes.

We report herein the development and validation of the comet assay within the canine and feline systems for future use in studying the effects that nutritional supplementation may have on protecting cells from free radical damage.

#### Materials and Methods

##### *Cell preparation*

All cats and dogs were housed at the Waltham Centre for Pet Nutrition, in conditions resembling those of pet cats and dogs, and were fed commercially available, complete diets throughout the study period. Small volume blood samples (5ml) were drawn from the jugular vein of 12 healthy adult cats ( $7.2 \pm 4.8$  years) and 12 healthy adult dogs ( $4.5 \pm 2.3$  years) into lithium heparin vials and diluted 1:1 in PBSa. Leukocytes were isolated over Histopaque 1083 gradients (Sigma, UK) by centrifugation at 1000g for 40 minutes. Leukocytes were washed twice in 10mls PBSa and centrifuged at 700g for 10 minutes before counting and storing at  $1 \times 10^6$  cells/ml in 90% foetal calf

serum (Sigma) and 10% dimethyl sulphoxide (Sigma) at  $-80^{\circ}\text{C}$  until required. Viability (assessed by trypan blue exclusion) was typically around 95%.

#### *Hydrogen peroxide treatment*

- 5 DNA damage was induced *ex vivo* by exposing the leukocytes to a range of  $\text{H}_2\text{O}_2$  concentrations (0-250 $\mu\text{M}$  diluted in PBSa) to determine the optimal level of  $\text{H}_2\text{O}_2$  required to induce a significant increase in DNA damage above background endogenous DNA damage levels. Leukocytes were thawed rapidly in a  $37^{\circ}\text{C}$  water bath, washed twice in PBSa, centrifuged at 700g for 15 minutes and resuspended in
- 10 PBSa at  $2 \times 10^5/\text{ml}$ . Cells were re-suspended in 0 $\mu\text{M}$ , 10 $\mu\text{M}$ , 50 $\mu\text{M}$ , 100 $\mu\text{M}$  and 250 $\mu\text{M}$   $\text{H}_2\text{O}_2$  in PBSa and incubated on ice for 5 minutes. Treated leukocytes were centrifuged at 700g for 15 minutes at  $4^{\circ}\text{C}$  ready for slide preparation.

#### *Slide preparation*

- 15 Two layers of agarose were prepared. For the first layer, 85 $\mu\text{l}$  1% (w/v) high-melting point (HMP) agarose (Sigma) prepared at  $95^{\circ}\text{C}$  in PBSa was pipetted onto fully frosted microscope slides, covered with an 18 x 18mm coverslip and allowed to set at  $4^{\circ}\text{C}$  for 10 minutes. Untreated and hydrogen peroxide-treated leukocytes were washed twice in PBSa, centrifuged at 700g for 15 minutes and resuspended at  $2 \times 10^5$  in 85 $\mu\text{l}$
- 20 1% (w/v) low melting point (LMP) agarose (Sigma). The cell suspension was then pipetted over the set HMP agarose layer, covered with an 18 x 18mm coverslip and allowed to set at  $4^{\circ}\text{C}$  for 10 minutes. After the coverslips were removed, the slides were immersed in freshly prepared cold lysis solution.

#### 25 *Cell lysis*

Slides were immersed in pre-chilled lysis solution (2.5M NaCl, 100mM sodium EDTA, 10mM Tris, pH adjusted to 10 using NaOH pellets, 1% Triton X-100 (v/v), (added immediately before use)) for 60 minutes at  $4^{\circ}\text{C}$  in order to remove cellular proteins.

*Alkaline treatment and electrophoresis*

Following lysis, the slides were placed in a gel electrophoresis unit and incubated in fresh alkaline electrophoresis buffer (300mM NaOH, 1mM EDTA, pH 13) for 40  
5 minutes at room temperature in the dark, before being electrophoresed at 25V (300mA) for 30 minutes at 4°C in the dark.

*Neutralisation and staining*

Following electrophoresis, the slides were immersed in neutralisation buffer (0.4M  
10 Tris-HCl, pH 7.5) and gently washed three times for 5 minutes at 4°C to remove alkalis and detergents. Fifty microlitres of SYBR Green (Trevigen, Gaithersburg, MD) was added to each slide to stain the DNA, then covered with a coverslip and kept in the dark in an air-tight moist container before viewing. SYBR Green was chosen for staining damaged DNA following studies by Ward, T.H. & Marples, B. (2000) SYBR  
15 Green I and the improved sensitivity of the single-cell electrophoresis assay. Int. J. Rad. Biol. 76: 61-65, demonstrating improved detection sensitivity and assay resolution of SYBR Green over alternative DNA stains.

*Scoring for DNA damage*

20 Visual and computerised image analysis of DNA damage was carried out in accordance with the protocols of Collins, A.R., Dunsiska, M., Gedik, C.M. & Stetina, R. (1996). Oxidative damage to DNA: do we have a reliable biomarker? Environ. Health Pers. 104 (Suppl 3): 465-469 and Collins, A., Dunsiska, M., Franklin, M., Somorovska, M., Petrouska, H., Duthie, S., Fillion, L., Panayiotidis, M., Raslova, K.  
25 & Vaughan, N. (1997). Comet assay in human biomonitoring studies: reliability, validation and applications. Envir. Mol. Mutagen. 30: 139-146. Slides were examined at 250x magnification on a Zeiss inverted fluorescence microscope at 460nm. Randomly selected non-overlapping cells were visually assigned a score on an arbitrary scale of 0-4 (i.e. ranging from 0 = no DNA damage, to 4 = extensive DNA  
30 damage) based on perceived comet tail length migration and relative proportion of

DNA in the comet tail. A total damage score for each slide was derived by multiplying the number of cells assigned to each grade of damage by the numeric value of the grade and summing over all grades (giving a maximum possible score of 400, corresponding to 100 cells at grade 4). To determine whether visual scoring correlated with computerised image analysis the same cells were also scored for DNA damage using the KOMET 4.0 analysis package (Kinetic Imaging, Liverpool, UK). A variety of objective measurements including, percentage DNA in tail, tail length (measured from the leading edge of the comet head), and tail moment were made. Tail moment was calculated as follows:

$$\text{Tail moment} = \text{Tail length} \times \% \text{ Tail DNA}/100$$

#### *Statistical analysis*

Linear regression analysis was used to correlate visual comet scores with computerised image analysis derived scores. A two-factor ANOVA as well as the Student-Newman-Keuls test were used in order to determine statistically significant differences between the different concentrations of H<sub>2</sub>O<sub>2</sub> used to induce *ex vivo* DNA damage.

#### **Results**

The objective of the present study was to develop and validate the use of the comet assay for assessing levels of DNA damage in feline and canine leukocytes. DNA damage is scored visually from class 0 (no DNA damage) to class 4 (extensive DNA damage) using perceived comet tail length and level of DNA in the tail as the scoring criteria. To demonstrate the susceptibility of feline and canine leukocytes to DNA damage, suspensions of cells were treated for 5 minutes with 0-250µM H<sub>2</sub>O<sub>2</sub>. SYBR green-stained comets were then assessed for DNA damage using the visual scoring system. Statistically significant increases in DNA damage ( $p < 0.001$ ) were observed over the range of 10-250µM H<sub>2</sub>O<sub>2</sub> in both feline and canine samples when compared

to untreated samples using the visual scoring system. While use of 250µM H<sub>2</sub>O<sub>2</sub> induced significant increases in DNA damage in relation to all other concentrations of H<sub>2</sub>O<sub>2</sub> used in both canine and feline samples (Figures 1 and 2), no significant differences were observed between the levels of DNA damage when comparing use of 10-100µM H<sub>2</sub>O<sub>2</sub> with the feline samples (Figure 1) and 50-100µM H<sub>2</sub>O<sub>2</sub> with the canine samples (Figure 2).

The second objective of this study was to compare visual scoring of comets (on a scale of 0-4) with computerised image analysis parameters of percentage DNA in tail, tail moment and tail length. Figures 3, 4 and 5 show that visual scoring of feline leukocyte comets were highly correlated with computer image analysis, as determined by linear regression, for percentage DNA in tail ( $R^2 > 0.99$ ), tail moment ( $R^2 > 0.95$ ) and tail length ( $R^2 > 0.90$ ), respectively. A similar trend was also observed when correlating the visual and computer image analysis of canine leukocyte comets, percentage DNA in tail ( $R^2 > 0.97$ ), tail moment ( $R^2 > 0.95$ ) and tail length ( $R^2 > 0.91$ ), Figures 6, 7 and 8, respectively.

### Example 2

Assessing levels of DNA damage in antioxidant supplemented versus control cats using the comet assay

#### *Animals*

All cats were housed at the Waltham Centre for Pet Nutrition, in conditions resembling those of pet cats. The test control group consisted of 14 adult domestic shorthaired cats ( $9.2 \pm 2.1$  years) and were maintained on a commercially available complete diet. The antioxidant supplemented group of 14 adult domestic shorthaired cats ( $8.7 \pm 1.9$  years) were maintained on the same commercial canned diet which

additionally contained the following antioxidant supplements (Table 1). All cats had been on their respective diets for over 2 years.

<u>Ingredient</u>	<u>mg/400kcal</u>
$\alpha$ -tocopherol	50
Ascorbate	40
$\beta$ -carotene	0.5
Lutein	0.5
Taurine	500
Lycopene	0.7

5 Table 1: levels of the Components of the antioxidant cocktail present in wet diet.

#### *Small volume blood samples*

Whole blood specimens were collected into a 5ml lithium heparin tube. The leukocyte cell fraction was then purified and separated from the whole blood for comet analysis.

10

#### *Comet assay*

The comet assay was performed as highlighted above in Example 1.

#### *Statistical analysis*

15 An independent two-sample t-test was used to compare the data sets. The results are shown in Figure 9 and Figure 10.

#### *Discussion*

20 Although a variety of bodily tissues have been suggested for use in the comet assay, blood leukocytes are considered a good marker of actual bodily state. Leukocytes are more susceptible to the damaging effects of free radicals because of the high percentage of polyunsaturated fatty acids in their plasma membranes and increased

production of free radicals as part of their normal function. Hydrogen peroxide is believed to be one of the most potent causes of DNA damage, chromosomal alterations and gene mutations by generating highly reactive hydroxyl radicals (OH<sup>•</sup>) close to the DNA molecule, via the Fenton reaction:

5



The results in the present report demonstrate a significant reduction in levels of endogenous and exogenous DNA damage in the supplemented group of cats compared to the non-supplemented group of control cats. This demonstrates significantly higher antioxidant resistance in the supplemented cats, leading to reduced susceptibility and exposure of DNA to endogenous and exogenous free radical attack, reducing the damage that potentiates DNA instability, mutation and dysfunction.

15 Endogenous DNA damage gives an indication that elevated levels of damage (or the elevated oxidative stress that causes the damage) contributes to the development of secondary diseases. This approach can be applied to the progression of degenerative disorders. In addition, DNA damage and mutation may result in:

- 20 (a) Failure of immunological cells to proliferate because of DNA-damage mediated cell-cycle arrest,
- (b) Decreased rates of proliferation, as a consequence of selection *in vivo* against cells carrying certain mutations may lead to sub-optimal
- 25 immune responses to infection,
- (c) Increased levels of apoptosis, triggered by critical levels of DNA damage may lead to reduced numbers of immunological cell-types.



In conclusion, reduction of endogenous and exogenous DNA damage levels through antioxidant supplementation in cats, may indicate reduced susceptibility to degenerative disorders, through reducing the susceptibility of DNA to free radical damage as well as possibly increasing the levels of DNA repair.

5

### Example 3

Assessing levels of DNA damage in antioxidant supplemented versus control puppies using the comet assay

10

Two groups of four, age and sex matched, Labrador retriever littermates were maintained to body weight on a complete balanced diet with supplements adjusted accordingly from 6 weeks of age until sampling for the comet assay at 15 months of age. One group was supplemented with an antioxidant cocktail, the ingredients of which are given in Table 2.

15

<u>Ingredient</u>	<u>mg/400kcal</u>
$\alpha$ -tocopherol	50
Ascorbate	40
$\beta$ -carotene	0.5
Lutein	0.5
Taurine	500

Table 2: Levels of the components of the cocktail.

20

### *Small volume blood samples*

Whole blood specimens were collected into a 5ml lithium heparin tube. The leukocyte cell fraction was then purified and separated from the whole blood for comet analysis.

*Comet assay*

The comet assay was performed as highlighted above in Example 1.

*Statistical analysis*

- 5 An independent two-sample t-test was used to compare the data sets.

The results are shown in Figure 11.

*Discussion*

- 10 The results in the present report demonstrate a reduction in levels of endogenous DNA damage in the supplemented group of puppies ( $p=0.150$ ) compared to non-supplemented group of control puppies.

- 15 In conclusion, reduction of endogenous DNA damage levels through supplementation in puppies, indicate reduced susceptibility to infection and degenerative disorders, including the ageing process in general, through reducing the susceptibility of DNA to free radical damage as well as possibly increasing the levels of DNA repair.

Example 4

20

Assessing levels of DNA damage in supplemented versus control adult dogs using the comet assay.

- 25 Two groups of 20, age and sex matched adult dogs of mixed breed were maintained to body weight on a complete balanced diet with supplements adjusted accordingly for a 16 week test phase. Sampling for the comet assay was carried out on at week 0 and at week 8. One group of dogs was supplemented with an antioxidant cocktail, the ingredients of which are given in Table 1.

<u>Ingredient</u>	<u>mg/400kcal</u>
$\alpha$ -tocopherol	50
Ascorbate	(20) 40
$\beta$ -carotene	0.5
Lutein	0.5
Taurine	(200) 500
Lycopene	0.7

The bracketed figures refer to concentration in dry diet format.

Table 1: Levels of the components of the cocktail.

5

*Small volume blood samples*

Whole blood specimens were collected into a 5ml lithium heparin tube. The leukocyte cell fraction was then purified and separated from the whole blood for comet analysis.

10

*Comet assay*

The comet assay was performed as highlighted above in Example 1.

*Statistical analysis*

An independent two-sample t-test was used to compare the data sets.

15

The results are shown in Figures 12 to 15.

The results in the present report demonstrate a significant reduction in levels of both endogenous ( $p=0.001$ ) and exogenous ( $p=0.003$ ) DNA damage in the AOX-supplemented group of dogs at 2 months post-supplementation, compared to the non-supplemented group of control dogs (Figure 13). No significant differences were noted in endogenous or exogenous DNA damage levels between the two groups at

20

baseline (Figure 12). Also the control group showed no significant change in either endogenous or exogenous levels of DNA damage when comparing samples taken at 2 months post-supplementation to baseline levels (Figures 14 and 15). However, when the 2 month supplementation levels of exogenous and endogenous DNA damage from the AOX-supplemented group of dogs were compared to their baseline values there were significant reductions in endogenous DNA damage ( $p=0.041$ ; Figure 14) and exogenous DNA damage ( $p=0.005$ ; Figure 15).

#### Example 5

10

Assessing levels of DNA damage in supplemented versus control dogs using the comet assay.

Following 8 weeks of supplementation, the AOX-supplemented dogs also showed significant reductions in both endogenous and exogenous DNA damage ( $P < 0.005$ ) compared to the control dogs as measured by the comet assay. These novel findings in dogs show that antioxidant supplementation exerts a protective effect of a decrease in DNA damage.

#### 20 Materials & Methods

##### *Animals*

Two groups of 20, age (mean  $4.4 \text{ y} \pm 1.85 \text{ y}$ ) and sex matched adult dogs of mixed breed were chosen for the study. All dogs had been vaccinated (canine distemper virus, parvovirus and adenovirus) and deemed clinically healthy. All dogs were housed at the WALTHAM Centre for Pet Nutrition, Leicestershire, UK, where the dogs were housed in purpose-built, environmentally enriched facilities and treated in accordance with the Centre's research ethics and UK Home Office regulations.

##### *Study design*

30 All dogs were offered a base diet that was nutritionally complete and balanced

consisting of wet (Pedigree®, Masterfoods, Melton Mowbray, UK) and dry (Chappie® Complete, Masterfoods, Peterborough, UK) manufactured diets in a 50:50 ratio on an energy basis. The base diet was offered for 12 weeks prior to commencement of the study at an allowance of 460 kJ predicted metabolizable energy per kgW<sup>0.75</sup>, designed to maintain normal body weight. The control group remained on the base diet for the 16-week test phase, whilst the antioxidant (AOX)-supplemented group simultaneously received the base diet and were orally supplemented with the antioxidant blend (vitamin C, vitamin E, taurine, lutein, lycopene and β-carotene) on a daily basis for the 16-week test phase. Dietary intakes were altered accordingly to account for any changes in body weight.

For DNA damage, samples were collected at weeks 0 and 8.

For analysis of DNA damage, small volume blood samples were collected at weeks 0 and 8 into lithium heparin tubes (LIP Ltd) and diluted 1:1 in phosphate buffered saline (PBSa). Leukocytes were isolated over Histopaque 1083 gradients (Sigma Chemical Co., UK) by centrifugation at 1000g for 40 minutes. Leukocytes were washed twice in 10mls PBSa and centrifuged at 700g for 10 minutes before counting and freezing slowly at 1x10<sup>6</sup> cells/ml in 90% fetal calf serum (Sigma) and 10% dimethyl sulphoxide (Sigma) to <-80°C until required. Viability (assessed by trypan blue exclusion) was typically around 98%. DNA damage, measured by the comet assay, was conducted according to Example 1. DNA strand breaks were analysed in untreated and H<sub>2</sub>O<sub>2</sub>-treated isolated canine leukocytes. Comets were scored based on a validated visual scoring system (100 cells per sample) using image analysis software (KOMET 4.0 analysis package (Kinetic Imaging, Liverpool, UK)) and the methods of Collins *et al*, 1996, 1997, *Supra*.

#### *Statistical analysis*

The data were evaluated using the SPSS for Windows (Version 10.0.0, SPSS Inc., Chicago, IL). When differences between groups were indicated by a significant time

by group interaction in the ANOVA, these were investigated in more detail by performing t-tests at each time point individually. Paired and unpaired t-tests were used to analyse DNA damage data. All variables were assessed for normality prior to analysis. Values were considered significant at  $P < 0.05$ . Data are reported as means  
5  $\pm$  SEM.

## Results

### *DNA damage*

No significant differences were noted in endogenous or exogenous DNA damage  
10 levels between the two groups at week 0 (Figure 16). After eight weeks of supplementation there was a significant reduction in levels of both endogenous ( $P < 0.005$ ) and exogenous ( $P < 0.005$ ) DNA damage in the AOX-supplemented group of dogs, compared to the control dogs (Figure 17). The control group of dogs showed no significant change in either endogenous or exogenous levels of DNA damage when  
15 comparing samples taken after 8 weeks of supplementation to baseline levels (data not shown). However, after 8 weeks of supplementation, when levels of exogenous and endogenous DNA damage from the AOX-supplemented group of dogs were compared to their own baseline values, significant reductions in endogenous DNA damage ( $P < 0.05$ ) (data not shown) and exogenous DNA damage ( $P < 0.005$ ) (data not shown)  
20 were observed.

## Discussion

The present data demonstrate that at week 0 (pre-supplementation) there were no differences in DNA damage between the two groups of dogs, but after 8 weeks of  
25 supplementation there was a significant reduction in both endogenous and exogenous DNA damage. A reduction in endogenous damage can indicate increased protection of DNA by antioxidants in the supplement against free radical attack, and/or increased rates of repair to damaged DNA. Challenging leukocytes *in vitro* with exogenous  $H_2O_2$  to induce DNA strand breaks also provides an indication of antioxidant  
30 protection or resistance to free radical damage.

Claims

1. Use of vitamin E, vitamin C and a carotenoid in the manufacture of a foodstuff  
5 for reducing nucleic acid damage in a companion animal.
2. Use, as claimed in claim 1, further comprising taurine.
3. Use, as claimed in claim 1 or claim 2 wherein the carotenoid is one or more of  
10 beta-carotene, lutein or lycopene.
4. Use, as claimed in any one of claims 1 to 3, wherein the vitamin E is present at  
a concentration of from 25IU/400kcal diet or above.
- 15 5. Use, as claimed in any one of claims 1 to 4, wherein the vitamin C is present at  
a concentration of from 10mg/400kcal or above.
6. Use, as claimed in any one of claims 1 to 5, wherein the carotenoid is present at  
a concentration of from 0.01mg/400kcal or above.  
20
7. Use, as claimed in any one of claims 2 to 6, wherein the taurine is present at a  
concentration of from 80mg/400kcal or above.
8. Use, as claimed in any one of claims 1 to 7, wherein the foodstuff is a dry, wet,  
25 or semi-dry foodstuff.
9. A method of reducing nucleic acid damage in an animal, the method  
comprising administering a foodstuff comprising vitamin E, vitamin C and a  
carotenoid to a companion animal.

10. A method, as claimed in claim 9, wherein the foodstuff further comprises taurine.
11. A method, as claimed in claim 9 or claim 10, wherein the carotenoid is one or more of beta-carotene, lutein or lycopene.
12. A method, as claimed in any one of claims 9 to 11, wherein vitamin E is present at a concentration of from 25IU/400kcal diet or above.
13. A method, as claimed in any one of claims 9 to 12, wherein vitamin C is present at a concentration of from 10mg/400kcal or above.
14. A method, as claimed in any one of claims 9 to 13, wherein carotenoid is present at a concentration of from 0.01mg/400kcal or above.
15. A method, as claimed in any one of claims 9 to 14, wherein taurine is present at a concentration of from 80mg/400kcal or above.
16. A method, as claimed in any one of claims 9 to 15, wherein the components are administered simultaneously, separately or sequentially.
17. Use of vitamin E, vitamin C and a carotenoid as hereinbefore described with reference to one or more of the examples.
18. A method of reducing nucleic acid damage in a companion animal as hereinbefore described with reference to one or more of the examples.



1 / 8




FIG. 1




FIG. 2

2 / 8




FIG. 3




FIG. 4

3 / 8




FIG. 5




FIG. 6

4 / 8




FIG. 7




FIG. 8

5 / 8




FIG. 9




FIG. 10




FIG. 11

6 / 8




FIG. 12




FIG. 13

7 / 8




FIG. 14




FIG. 15

8 / 8




FIG. 16




FIG. 17



## INTERNATIONAL SEARCH REPORT

PCT/GB 02/03579

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A23K1/16 A23K1/18

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A23K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

BIOSIS, WPI Data, PAJ, EPO-Internal, FSTA

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 00 44375 A (HARPER E JEAN ;MARS UK LTD (GB)) 3 August 2000 (2000-08-03) claims 1-15 ---	1-18
X	US 6 261 598 B1 (RUNGE FRANK ET AL) 17 July 2001 (2001-07-17) column 1, line 12-16 column 2, line 62-64 claims 1,7; example 4 ---	1-18
X	US 5 834 044 A (ZEMENEK ELIZABETH ET AL) 10 November 1998 (1998-11-10) column 6, line 1-6 claim 1; example 7 --- -/--	1,3-9, 11-18



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

## \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*8\* document member of the same patent family

Date of the actual completion of the international search

4 December 2002

Date of mailing of the international search report

13/01/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Rooney, K

## INTERNATIONAL SEARCH REPORT

PCT/GB 02/03579

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>ZHANG, P., AND OMAVE, S. T.: "DNA strand breakage and oxygen tension: effects of beta-carotene, alpha-tocopherol and ascorbic acid"</p> <p>FOOD AND CHEMICAL TOXICOLOGY., vol. 39, no. 3, 2001, pages 239-246, XP002223247</p> <p>ISSN: 0278-6915</p> <p>page 240, column 2, paragraph 2 -page 241, column 2, paragraph 2</p> <p>page 244, column 1, paragraph 2; table 1</p> <p>page 244, column 2, paragraph 5 -page 245, column 1, paragraph 2</p> <p>---</p>	<p>1,3,8,9, 11,16-18</p>
A	<p>DATABASE BIOSIS 'Online!</p> <p>BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; August 2000 (2000-08)</p> <p>BASKIN CAROLE R ET AL: "Effects of dietary antioxidant supplementation on oxidative damage and resistance to oxidative damage during prolonged exercise in sled dogs."</p> <p>Database accession no. PREV200000381119</p> <p>XP002223249</p> <p>abstract</p> <p>&amp; AMERICAN JOURNAL OF VETERINARY RESEARCH, vol. 61, no. 8, August 2000 (2000-08), pages 886-891, ISSN: 0002-9645</p> <p>---</p>	<p>1-18</p>
A	<p>PRASAD, K.N., KUMAR, A., KOCHUPILLAI, V., AND COLE, W. C. : "High dose of multiple antioxidant vitamins: essential ingredients in improving the efficacy of standard cancer therapy"</p> <p>JOURNAL OF THE AMERICAN COLLEGE OF NUTRITION., vol. 18, no. 1, 1999, pages 13-25, XP002223248</p> <p>AMERICAN COLLEGE OF NUTRITION, WILMINGTON, NC., US</p> <p>ISSN: 0731-5724</p> <p>See whole document</p> <p>---</p> <p style="text-align: center;">-/--</p>	<p>1-18</p>

## INTERNATIONAL SEARCH REPORT

PCT/GB 02/03579

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>DATABASE FSTA 'Online! INTERNATIONAL FOOD INFORMATION SERVICE (IFIS), FRANKFURT/MAIN, DE; ZHANG S ET AL: "Dietary carotenoids and vitamins A, C, and E and risk of breast cancer." Database accession no. 1999-00-a1038 XP002223250 abstract &amp; JOURNAL OF THE NATIONAL CANCER INSTITUTE 91 (6) 547-556 1999 DEP. OF NUTR., HARVARD SCH. OF PUBLIC HEALTH, 665 HUNTINGTON AVE., BOSTON, MA 02115, USA. E-MAIL SHUMIN.ZHANG(A)CHANNING.HARVARD.EDU,</p>	1-18
A	<p>----- EP 1 120 107 A (JOHNSON &amp; JOHNSON CONSUMER FRA) 1 August 2001 (2001-08-01) page 1, paragraphs 3,13 page 2, line 36-44 claim 1 -----</p>	1-18

# INTERNATIONAL SEARCH REPORT

PCT/GB 02/03579

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: **9-16 and 18**  
because they relate to subject matter not required to be searched by this Authority, namely:  
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

**FURTHER INFORMATION CONTINUED FROM PCT/SA/ 210**

Continuation of Box I.1

Although claims 9-16 and 18 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

-----

Continuation of Box I.1

Claims Nos.: 9-16 and 18

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy

# INTERNATIONAL SEARCH REPORT

Information on patent family members

PCT/GB 02/03579

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0044375	A	03-08-2000	AU 2304200	A 18-08-2000
			BR 0007862	A 23-10-2001
			CN 1342073	T 27-03-2002
			EP 1146870	A1 24-10-2001
			WO 0044375	A1 03-08-2000
			GB 2366179	A 06-03-2002
			HU 0200075	A2 29-05-2002
			JP 2002535364	T 22-10-2002
US 6261598	B1	17-07-2001	DE 19838636	A1 02-03-2000
			CN 1251745	A 03-05-2000
			EP 0981969	A1 01-03-2000
			JP 2000086505	A 28-03-2000
			KR 2000017541	A 25-03-2000
			US 2001019724	A1 06-09-2001
US 5834044	A	10-11-1998	US 5643623	A 01-07-1997
			AU 725019	B2 05-10-2000
			AU 5880696	A 30-12-1996
			EP 0831726	A1 01-04-1998
			JP 11506925	T 22-06-1999
			PL 324969	A1 22-06-1998
			WO 9639869	A1 19-12-1996
EP 1120107	A	01-08-2001	FR 2804023	A1 27-07-2001
			EP 1120107	A1 01-08-2001
			US 2002044980	A1 18-04-2002